Import Rafinlar 50mg to USA | Ernest Oncology Bulk Targeted Therapy

Rafinlar 50mg Capsule: Precision Targeted Therapy for BRAF-Mutant Cancers

Are you searching for a reliable Rafinlar 50mg Capsule exporter from India? Ernest Oncology, a dedicated vertical of Ernest Pharmaceutical Pvt. Ltd., is a globally recognized supplier and bulk distributor of advanced oncology medications. We maintain a high-authority, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving targeted therapies reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Rafinlar 50mg?

Rafinlar 50mg contains the active pharmaceutical ingredient Dabrafenib. It is a potent, selective, and reversible inhibitor of the BRAF kinase, a protein that plays a critical role in the growth and spread of cancer cells.

Manufactured by Novartis, Rafinlar is a world-class targeted therapy specifically designed for patients with tumors expressing the BRAF V600 mutation. For international B2B procurement, Rafinlar 50mg offers a clinically validated solution for personalized cancer care, often used in combination with other agents to improve patient outcomes.

Primary Therapeutic Indications

Rafinlar 50mg Capsule is clinically indicated for:

1. Unresectable or Metastatic Melanoma: Treatment of patients with BRAF V600E mutation-positive melanoma that cannot be removed by surgery or has spread to other parts of the body.

2. Adjuvant Treatment of Melanoma: Used after surgery to prevent the recurrence of BRAF V600E or V600K mutation-positive melanoma.

3. Metastatic Non-Small Cell Lung Cancer (NSCLC): In combination with trametinib for patients with metastatic NSCLC whose tumors have the BRAF V600E mutation.

4. Anaplastic Thyroid Cancer (ATC): In combination with trametinib for patients with locally advanced or metastatic ATC.

Mechanism of Action: How Rafinlar 50mg Works

Rafinlar belongs to a class of drugs known as kinase inhibitors. It targets the MAPK (Mitogen-Activated Protein Kinase) signaling pathway:

• Blocking the "Growth Switch": In many cancers, the BRAF protein is mutated (most commonly V600E), causing it to be permanently "on." This sends constant signals to cells to divide uncontrollably.

• Inhibiting Signaling: Rafinlar binds to the mutated BRAF protein, effectively "switching off" the signaling pathway.

• Tumor Regression: By interrupting these growth signals, the medication slows or stops the proliferation of cancer cells, leading to tumor shrinkage and delayed disease progression.

Administration and Safety Guidelines

• Dosage: Typically taken as 150 mg twice daily (three 50 mg capsules per dose). It should be taken at least 1 hour before or 2 hours after a meal.

• Swallow Whole: Capsules must not be opened, crushed, or chewed.

• Key Precautions:

• Febrile Reactions: Severe fever (pyrexia) is a common side effect; monitor temperature closely.

• New Malignancies: Kinase inhibitors can occasionally cause new skin cancers; regular dermatologic exams are required.

• Hyperglycemia: Monitor blood glucose levels, especially in diabetic patients.

• Uveitis: Report any vision changes immediately, as inflammation of the eye can occur.

• Storage: Store at room temperature away from moisture and light.

Why Source Rafinlar 50 mg from Ernest Oncology?

• Verified Indian Exporter: Authentic supply of Novartis brands, ensuring 100% product integrity and competitive wholesale pricing.

• Global Logistics Mastery: Deep expertise in navigating the specialized regulatory landscapes of the USA, UK, Australia, and South Africa.

• Integrity & Trust: As a division of Ernest Pharmaceutical Pvt. Ltd., we adhere to the highest ethical standards in pharmaceutical distribution.

• B2B Reliability: We specialize in fulfilling large-scale orders for oncology centers, government tenders, and regional distributors.